Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BoneZone
NCT04608630Phase 2Recruiting
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Start
- Jul 2021
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of denosumab, zoledronic acid in osteoporosis, sponsored by Australian and New Zealand Intensive Care Research Centre. Started Jul 2021; status: recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04608630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608630.